<
AI
Automation
Science
Innovation
Open Source
Blockchain
Social Media
Startups
Culture
Cloud
>

Destination
Eli Lilly and Novo Nordisk are tackling heart health next

After revolutionizing the weight-loss drug market, Novo Nordisk (NVO) and Eli Lilly (LLY) are setting their sights on heart health.Read more... [...]

Discover Copy
Rating

Innovation

Pricing

Technology

Usability

We have discovered similar tools to what you are looking for. Check out our suggestions for similar AI tools.

Destination
How to use the AirPods Pro 3’s heart rate tracking feature

Your AirPods may soon become your most important pieces of fitness gear. One of the AirPods Pro 3’s new features is heart rate tracking for both workouts and periodic pulse checks. Apple’s latest [...]

Match Score: 142.75

Destination
How Ozempic maker Novo Nordisk fell behind Eli Lilly in the weight loss drug race

Novo Nordisk (NVO) makes Ozempic, the best-known GLP-1 drug out today. And until quite recently, the Danish pharma giant consistently led the pack in new prescriptions, becoming virtually synonymous w [...]

Match Score: 119.39

Destination
Eli Lilly's Zepbound beat Novo Nordisk’s Wegovy in a big weight loss drug study

Eli Lilly’s (LLY) and Novo Nordisk’s (NVO) weight loss drugs went head-to-head in a weight loss study for the first time — and Eli Lilly’s drug came out on top.Read more... [...]

Match Score: 103.34

thenextweb
Hacking group claims it breached Novo Nordisk and demanded $25m

A cyber-extortion group calling itself FulcrumSec said on Monday that it had stolen roughly 1.3 terabytes of data from Novo Nordisk, the Danish maker of the weight-loss drugs Wegovy and Ozempic, and h [...]

Match Score: 91.24

thenextweb
Novo Nordisk hands shelved Parkinson’s cell therapy to Zuckerberg-backed Cellular Intelligence

Novo will take an equity stake in Cellular Intelligence and is in line for future milestone payments and royalties. The startup plans to apply its AI platform to STEM-PD, a stem-cell-derived treatment [...]

Match Score: 91.08

Destination
Novo Holdings' earnings nearly doubled in 2024, despite Novo Nordisk's stock slump

Novo Holdings, the controlling shareholder of Ozempic-maker Novo Nordisk (NVO), nearly doubled its annual income and investment returns in 2024.Read more... [...]

Match Score: 90.58

Destination
Novo Nordisk and Eli Lilly ink deals with Trump to cut weight loss drug prices

Prices of Eli Lilly's and Novo Nordisk's GLP-1 drugs will drop in some cases — in exchange for partially expanded Medicare coverage [...]

Match Score: 74.53

Destination
An Ozempic successor falls short, Eli Lilly's GLP-1 pill, and senators grill RFK: Pharma news roundup

An Eli Lilly exec said the company’s experimental weight-loss pill could make GLP-1 treatments more accessible worldwide, as it would be easier to manufacture and distribute globally. Three U.S. sen [...]

Match Score: 74.22

Destination
Eli Lilly's weight loss pill could be just as good as Ozempic — and the stock soars

The first GLP-1 pill could be in medicine cabinets sooner than expected.Read more... [...]

Match Score: 74.03